Just three years ago, DNA testing company 23andMe was the golden child of Wall Street and Main Street. Today, the company is struggling to remain listed on the Nasdaq.
If you read the article, they partner with GSK. So it’s probably only going to them, not the open market. They openly say they’re researching genetic meds.
If you read the article, they partner with GSK. So it’s probably only going to them, not the open market. They openly say they’re researching genetic meds.